• About us
• Contact

Advertisement

Organisation › Details

DeveloGen AG

DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine diseases. The Company has a highly innovative and deep preclinical discovery pipeline addressing the key drivers in the development of diabetes and obesity such as insulin resistance and loss of insulin-producing beta cells. This pipeline includes programs for the potential treatment of obesity through orally available small molecules based on novel and proprietary targets as well as growth factors targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Göttingen, Germany. *

 

	Start	1998-01-01 start
	End	2012-01-24 renamed
	Group	Evotec (Group)
	Today	Evotec (Göttingen) AG
	Predecessor	Max Planck Institute for Biophysical Chemistry (MPI-BPC) (Goettingen)
	Successor	Evotec (Göttingen) AG
	Industry	biopharmaceutical
	Region	Göttingen
	Country	Germany
	Street	7 Marie-Curie-Str.
	City	37079 Göttingen
	Tel	+49-551-50558-0
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for Evotec (Group)

• [1] Indivumed GmbH. (4/8/25). "Press Release: Indivumed Celebrates Milestone of Its Patient-Centric R&D Platform. Numerous Novel Cancer Targets Discovered for First-in-Class Therapeutics". Hamburg....
• [2] Evotec SE. (2/25/25). "Press Release: Evotec Announces Change in Management Board". Lüneburg....
• [3] Evotec SE. (11/29/24). "Press Release: Evotec Announces Change in Management Board. Dr Craig Johnstone Steps Down as Chief Operating Officer Effective 31 December 2024". Hamburg....
• [4] Halozyme Therapeutics, Inc.. (11/22/24). "Press Release: Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions". San Diego, CA....
• [5] Halozyme Therapeutics, Inc.. (11/18/24). "Press Release: Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec". San Diego, CA....
• [6] Halozyme Therapeutics, Inc.. (11/14/24). "Press Release: Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction". San Diego, CA....
• [7] Evotec SE. (9/26/24). "Press Release: Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-generation Cell Therapies". Hamburg....
• [8] Evotec SE. (9/3/24). "Press Release: Evotec Announces Change in Management Board. Dr Matthias Evers Steps Down as Chief Business Officer Effective 01 October 2024". Hamburg....
• [9] Evotec SE. (7/8/24). "Press Release: Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz". Hamburg & Seattle, WA....
• [10] Evotec SE. (6/25/24). "Press Release: Just – Evotec Biologics Selected by U.S. Department of Defense for Manufacturing Optimization Program". Hamburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.